

References

- Casey, R. (2023, May 9). *A Quick Guide to Human Leukocyte Antigen (HLA) Typing Techniques*. The Sequencing Center.
<https://thesequencingcenter.com/a-quick-guide-to-human-leukocyte-antigen-hla-typing-techniques/>
- Chen, H., Yang, J., Zhang, S., Qin, X., Jin, W., Sun, L., Li, F., & Cheng, Y. (2019). Serological cytokine profiles of cardiac rejection and lung infection after heart transplantation in rats. *Journal of Cardiothoracic Surgery*, 14(1), 26. <https://doi.org/10.1186/s13019-019-0839-5>
- Chong, A. S. (2020). B cells as antigen-presenting cells in transplantation rejection and tolerance. *Cellular Immunology*, 349, 104061.
<https://doi.org/10.1016/j.cellimm.2020.104061>
- Costa, C. D. (2019, August 26). What Is Machine Learning & Deep Learning? Medium.
<https://medium.com/@clairedigitalogy/what-is-machine-learning-deep-learning-7788604004da>
- Dasgupta, A. (2016). Chapter 2 - Limitations of immunoassays used for therapeutic drug monitoring of immunosuppressants. In M. Oellerich & A. Dasgupta (Eds.), *Personalized Immunosuppression in Transplantation* (pp. 29–56). Elsevier.
<https://doi.org/10.1016/B978-0-12-800885-0.00002-3>
- Duquesnoy, R. J., & Askar, M. (2007). HLAMatchmaker: A Molecularly Based Algorithm for Histocompatibility Determination. V. Eplet Matching for HLA-DR, HLA-DQ, and HLA-DP. *Human Immunology*, 68(1), 12–25.
<https://doi.org/10.1016/j.humimm.2006.10.003>
- Gautreaux, M. D. (2017). Chapter 17 - Histocompatibility Testing in the Transplant Setting. In G.

Orlando, G. Remuzzi, & D. F. Williams (Eds.), *Kidney Transplantation, Bioengineering and Regeneration* (pp. 223–234). Academic Press.

<https://doi.org/10.1016/B978-0-12-801734-0.00017-5>

General, Non-specific Defenses Against Infection. (n.d.). Defense Mechanism. Retrieved January 26, 2024, from

https://sphweb.bumc.bu.edu/otlt/mph-modules/ph/ph709_defenses/ph709_defenses_print.html

Geneugelijk, K., & Spierings, E. (2020). PIRCHE-II: an algorithm to predict indirectly recognizable HLA epitopes in solid organ transplantation. *Immunogenetics*, 72(1), 119–129. <https://doi.org/10.1007/s00251-019-01140-x>

Grinyo, J. M. (2013). Why Is Organ Transplantation Clinically Important? *Cold Spring Harbor Perspectives in Medicine*, 13(11). <https://doi.org/10.1101/cshperspect.a014985>

Hewitt, E. W. (2003). The MHC class I antigen presentation pathway: strategies for viral immune evasion. *Immunology*, 110(2), 163–169.

<https://doi.org/10.1046/j.1365-2567.2003.01738.x>

Hunt, D., & Saab, S. (2012). Post–Liver Transplantation Management - ScienceDirect. In *Zakim and Boyer's Hepatology* (Sixth, pp. 869–882).

<https://www.sciencedirect.com/science/article/abs/pii/B9781437708813000498>

Ingulli, E. (2010). Mechanism of cellular rejection in transplantation | Pediatric Nephrology. *Pediatric Nephrology*, 25. <https://doi.org/10.1007/s00467-008-1020-x>

Kelly, J. (2022, April 27). *End of anti-rejection transplant drugs? A clinical trial at Hume-Lee hopes so.* VCU Health.

<https://www.vcuhealth.org/news/end-of-anti-rejection-transplant-drugs-a-clinical-trial-at->

hume-lee-hopes-so

Kramer, Cynthia S. M., et al. “HLA-EMMA: A User-friendly Tool to Analyse HLA Class I and Class II Compatibility on the Amino Acid Level.” *Hla*, vol. 96, no. 1, July 2020, pp.

43–51, <https://doi.org/10.1111/tan.13883>

Manski, C. F., Tambur, A. R., & Gmeiner, M. (2019). Predicting kidney transplant outcomes

with partial knowledge of HLA mismatch. *Proceedings of the National Academy of*

Sciences, 116(41), 20339–20345. <https://doi.org/10.1073/pnas.1911281116>

Matching and Compatibility. (n.d.). UC Davis Health. Retrieved November 8, 2023, from

<https://health.ucdavis.edu/transplant/livingkidneydonation/matching-and-compatibility.html>

Nunes, E., Heslop, H., Fernandez-Vina, M., Taves, C., Wagenknecht, D. R., Eisenbrey, A. B.,

Fischer, G., Poulton, K., Wacker, K., Hurley, C. K., Noreen, H., & Sacchi, N. (2011).

Definitions of histocompatibility typing terms. *Blood*, 118(23), e180–e183.

<https://doi.org/10.1182/blood-2011-05-353490>

Organ, Eye and Tissue Donation Statistics. (n.d.). Donate Life America. Retrieved November 8, 2023, from <https://donatelife.net/donation/statistics/>

Organ Rejection after Renal Transplant. (n.d.). Columbia Surgery. Retrieved November 8, 2023,

from <https://columbiasurgery.org/kidney-transplant/organ-rejection-after-renal-transplant>

Reits, E., & Neefjes, J. (2022). HLA molecules in transplantation, autoimmunity and infection

control: A comic book adventure. *Hla*, 100(4), 301–311.

<https://doi.org/10.1111/tan.14626>

Spitznagel, T., Matter, L. S., Kaufmann, Y. L., Nilsson, J., von Moos, S., & Schachtner, T.

(2022). PIRCHE-II scores prove useful as a predictive biomarker among kidney

transplant recipients with rejection: An analysis of indication and follow-up biopsies.

Frontiers in Immunology, 13, 949933. <https://doi.org/10.3389/fimmu.2022.949933>

Understanding Transplant Rejection. (n.d.). Stony Brook Medicine. Retrieved November 8,

2023, from <https://www.stonybrookmedicine.edu/patientcare/transplant/rejection>

Unterrainer, C., Döhler, B., Niemann, M., Lachmann, N., & Süsal, C. (2021). Can PIRCHE-II

Matching Outmatch Traditional HLA Matching? *Frontiers in Immunology*, 12.

<https://www.frontiersin.org/articles/10.3389/fimmu.2021.631246>

Viatte, S. (2023, September 8). Human leukocyte antigens (HLA): A roadmap - UpToDate.

UpToDate.

<https://www.uptodate.com/contents/human-leukocyte-antigens-hla-a-roadmap/print>

Vijayan, S., Sidiq, T., Yousuf, S., van den Elsen, P. J., & Kobayashi, K. S. (2019). Class transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance. *Immunogenetics*, 71(3), 273–282.

<https://doi.org/10.1007/s00251-019-01106-z>

Why Is Organ Donation Important? (2022, March 29). INTEGRIS Health.

[https://integrisk.com/resources/on-your-health/2022/march/why-is-organ-donation-importan](https://integrisk.com/resources/on-your-health/2022/march/why-is-organ-donation-important)

Zaza, G., Tomei, P., Granata, S., Boschiero, L., & Lupo, A. (2014). Monoclonal Antibody

Therapy and Renal Transplantation: Focus on Adverse Effects. *Toxins*, 6(3).

<https://doi.org/10.3390/toxins6030869>